ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Tyrosine kinase inhibitors (TKIs) are standard therapy for chronic myeloid leukemia (CML).
• Resistance to TKIs in CML often arises from mutations in the BCR-ABL1 fusion gene transcript.
• Identifying these mutations is vital for managing treatment resistance.

Purpose of the Study:

• To investigate the frequency and types of BCR-ABL1 mutations in CML patients experiencing TKI treatment failure or suboptimal response.
• To assess the clinical relevance of BCR-ABL1 mutations in CML treatment resistance.

Main Methods:

• Analysis of blood samples from 43 CML patients with documented poor response to TKIs.
• Utilized semi-nested PCR assay for mutation screening.
• Employed Sanger sequencing for precise genetic mutation identification.

Main Results:

• Identified 15 BCR-ABL1 mutations in 32.55% of the studied CML patients.
• The detected mutations included 14 point mutations and one exon 7 deletion.
• These findings confirm that BCR-ABL1 mutations are a significant cause of TKI resistance in CML.

Conclusions:

• BCR-ABL1 mutations are frequently observed in CML patients with suboptimal or failed TKI therapy.
• Genetic screening for BCR-ABL1 mutations should be considered in CML patients who do not respond adequately to TKIs.
• Understanding mutation profiles can guide alternative treatment strategies for resistant CML.